QOLP-03. END OF LIFE PHASE IN GLIOBLASTOMA: PROSPECTIVE ASSESSMENT OF SYMPTOM BURDEN AND SYMPTOM INTERFERENCE IN THE END OF LIFE PHASE- FINAL ANALYSIS

摘要

PURPOSE: To prospectively study symptoms and quality of life in terminal stage Glioblastoma (GBM) patients. End-of-life (EoL) symptoms of patients with GBM are poorly understood and have not been prospectively assessed in larger outpatient cohorts. The aim of this study was to assess prominent EoL symptoms in GBM to guide future treatment decisions and palliative care guidelines.METHODSProspective single-center study assessing symptoms and QoL of GBM patients with low performance status (Karnofsky Performance Status 3rd line therapy with bevacizumab and showing clinical and radiological progression. The MD Anderson Symptom Inventory Brain Tumor Module and neurological assessments were used upon enrollment and during bi-weekly phone calls with patients and caregivers. Mixed models were used to assess changes over time for symptoms and interferences over the last 14 weeks prior to death.